PRQR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ProQR Therapeutics NV (PRQR) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite a positive analyst rating and promising RNA editing platform, the technical indicators, financial performance, and lack of significant trading trends or catalysts suggest a cautious approach. The stock's pre-market price increase is not supported by strong momentum or signals, and the financials indicate ongoing challenges. Holding off for clearer signs of growth or stability is recommended.
The MACD is negatively expanding (-0.0224), RSI is neutral (30.658), and moving averages are converging, indicating no clear trend. The stock is trading near its key support level (S1: 1.662), with resistance levels at R1: 2.013 and R2: 2.122. Overall, the technical indicators suggest a lack of strong upward momentum.
Positive analyst rating with an Outperform rating and a $9 price target. Strong preclinical data and a unique RNA editing platform targeting unmet medical needs.
No recent news or significant trading trends from hedge funds or insiders. Financial performance shows a decline in net income (-4.14% YoY) and EPS (-11.11% YoY). Congress trading data is unavailable, and there are no recent influential figure transactions.
In Q4 2025, revenue increased by 6.14% YoY to $4.716M, but net income dropped to -$8.92M (-4.14% YoY), and EPS declined to -0.08 (-11.11% YoY). Gross margin remained stable at 100%.
Oppenheimer analyst Kostas Biliouris assumed coverage with an Outperform rating and a $9 price target, citing strong preclinical data and potential to address significant unmet medical needs.
